Genenta Science, a clinical-stage immuno-oncology company, has received Orphan Drug Designation (ODD) from the European Commission for its product Temferon™, which is used in the treatment of glioma, specifically Glioblastoma Multiforme (GBM).
Temferon™ is a cell-based therapy that utilizes hematopoietic stem cells to treat solid tumors. It modifies the patient’s own stem progenitor cells with Genenta’s platform to express interferon alpha (IFNa) within solid tumors. IFNa is an immunomodulatory protein with a history of use in cancer treatment but limited by systemic toxicity. Genenta’s platform is designed to overcome this limitation and selectively deliver therapeutic activity within the tumor, breaking tumor-induced tolerance and enabling the immune system to mount a durable response.
Temferon™ is currently being investigated in clinical trials for Glioblastoma Multiforme (GBM) patients and aims to induce a durable immune response, unrestricted by pre-selected tumor antigens or types, while avoiding systemic toxicity.